Viva Biotech HoldingsFRA:VB0 +4.88%43 Return-on-Tangible-Equity is 13.42% as of Dec. 2025, which is 29% below its 10-year median of 18.93. GuruFocus rates FRA:VB0 with a GF Score™ of 43/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,199 Biotechnology companies, Viva Biotech Holdings ranks better than 89.66% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Viva Biotech Holdings's annualized net income for the quarter that ended in Dec. 2025 was €23.8 Mil. Viva Biotech Holdings's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €177.1 Mil. Therefore, Viva Biotech Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 13.42%.
The historical rank and industry rank for Viva Biotech Holdings's Return-on-Tangible-Equity or its related term are showing as below:
FRA:VB0'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -45.64 Med: 18.93 Max: 67.74
Current: 15.8
During the past 10 years, Viva Biotech Holdings's highest Return-on-Tangible-Equity was 67.74%. The lowest was -45.64%. And the median was 18.93%.
FRA:VB0's Return-on-Tangible-Equity is ranked better than 89.66% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs FRA:VB0: 15.80
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Viva Biotech Holdings Return-on-Tangible-Equity Related Terms
Viva Biotech Holdings Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB0 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 13.42% mean?
Viva Biotech Holdings (FRA:VB0) has a Return-on-Tangible-Equity of 13.42% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Viva Biotech Holdings and its competitors. This is 29% below median its historical median of 18.93. According to the industry distribution chart, Viva Biotech Holdings ranks #124 out of 1199 companies in the Biotechnology industry, placing it in the top 10.3%.
Is Viva Biotech Holdings' Return-on-Tangible-Equity too high?
Viva Biotech Holdings' current Return-on-Tangible-Equity of 13.42% is 29% below median its 10-year median of 18.93. Based on the distribution chart, Viva Biotech Holdings ranks #124 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Viva Biotech Holdings has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #124 out of 1199 companies for Return-on-Tangible-Equity. This places Viva Biotech Holdings in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Viva Biotech Holdings and its competitors. Viva Biotech Holdings's current Return-on-Tangible-Equity is 13.42%, which is 29% below median its own 10-year median of 18.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.13 — trading 61.3% above its estimated fair value. The current Return-on-Tangible-Equity is 13.42%, which is 29% below median its 10-year median of 18.93. Viva Biotech Holdings' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Return-on-Tangible-Equity is 13.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.13 is trading 61.3% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
Return-on-Tangible-Equity: 13.42% (29% below median its 10-year median of 18.93)
GF Value™: €0.08 vs. price of €0.13 (61.3% above fair value)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
43GF Score
Get the complete analysis for FRA:VB0
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
